Infusion Experience

2 doses a year, 2 more reasons to choose UPLIZNA1

Twice-yearly dosing with UPLIZNA offers
patients more infusion-free time1

NMOSD patient, Jasmine

Jasmine
UPLIZNA patient since 2021. Individual
results may vary. Hear how UPLIZNA helped Jasmine regain her lifestyle.

NMOSD patient, Jasmine

Jasmine
UPLIZNA patient since 2021. Individual
results may vary. Hear how UPLIZNA
helped Jasmine regain her lifestyle.

Graphic showing the UPLIZNA dosing schedule, with initial doses on Day 1 and Day 15 and maintenance dosing every 6 months after the first doseGraphic showing the UPLIZNA dosing schedule, with initial doses on Day 1 and Day 15 and maintenance dosing every 6 months after the first dose

6-month maintenance infusions
of only
90 minutes each1

Treatment comparison among UPLIZNA and other FDA-approved therapies for NMOSD1-4
UPLIZNA®
(inebilizumab-cdon)		 ENSPRYNG®
(satralizumab-mwge)		 SOLIRIS®
(eculizumab)		 ULTOMIRIS®
(ravulizumab-cwvz)
Presumed mechanism of action CD19+ B-cell depletion Anti-IL-6R C5 inhibitor C5 inhibitor
Initial dose 2 doses, 2 weeks apart 3 doses, 2 weeks apart 5 doses, 1 week apart 2 doses, 2 weeks apart
Maintenance dose Every 6 months
(~2 doses per year)		 Every 4 weeks
(~12 doses per year)		 Every 2 weeks
(~24 doses per year)		 Every 8 weeks
(~6 to 7 doses/yr)
Mode of administration IV infusion SC injection IV infusion IV infusion
Presumed mechanism of action UPLIZNA®
(inebilizumab-cdon) 		CD19+ B-cell
depletion		 ENSPRYNG®
(satralizumab-mwge) 		Anti-IL-6R SOLIRIS®
(eculizumab) 		C5 inhibitor ULTOMIRIS®
(ravulizumab-cwvz) 		C5 inhibitor
Initial dose UPLIZNA®
(inebilizumab-cdon) 		2 doses,
2 weeks apart		 ENSPRYNG®
(satralizumab-mwge) 		3 doses,
2 weeks apart		 SOLIRIS®
(eculizumab) 		5 doses,
1 week apart		 ULTOMIRIS®
(ravulizumab-cwvz) 		2 doses,
2 weeks apart
Maintenance dose UPLIZNA®
(inebilizumab-cdon) 		Every 6 months
(~2 doses per year)		 ENSPRYNG®
(satralizumab-mwge) 		Every 4 weeks
(~12 doses per year)		 SOLIRIS®
(eculizumab) 		Every 2 weeks
(~24 doses per year)		 ULTOMIRIS®
(ravulizumab-cwvz) 		Every 8 weeks
(~6 to 7 doses/yr)
Mode of administration UPLIZNA®
(inebilizumab-cdon) 		IV infusion ENSPRYNG®
(satralizumab-mwge) 		SC injection SOLIRIS®
(eculizumab) 		IV infusion ULTOMIRIS®
(ravulizumab-cwvz) 		IV infusion

No head-to-head studies have been conducted; therefore, comparisons of safety or effectiveness should not be made.

More reasons to choose this FDA-approved treatment chosen by more than 1475 patients5

Clinical experience icon

CLINICAL EXPERIENCE

UPLIZNA has established safety and efficacy profiles, with more than 6000 doses administered since 20205

Persistence icon

~95% PERSISTENCE

Approximately 95%

of patients who started on UPLIZNA stayed on UPLIZNA (data from US patients enrolled in Amgen by Your Side)5*

Chosen by specialists icon

CHOSEN BY SPECIALISTS

UPLIZNA is well-established in NMOSD specialty care, prescribed by more than 600 neurologists/neuro-ophthalmologists5

*Data from 10/01/2023-09/30/2024 for 1,307 patients enrolled in Amgen By Your Side who received a dose of UPLIZNA within 6 months of the start date and received or are scheduled to receive their next dose within 6 months of the end date of the analysis.

Access support icon

UPLIZNA is supported by >2275 patient-years of experience in NMOSD5

Enroll Patient

Download the form, complete it with your patient, including HCP signature, and submit it by fax or email.

Sign Up Now

Learn about how
UPLIZNA is administered

IV, intravenous; NMOSD, neuromyelitis optica spectrum disorder; SC, subcutaneous.

Tx Recommendations

INDICATION UPLIZNA (inebilizumab-cdon) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

IMPORTANT SAFETY INFORMATION UPLIZNA is contraindicated in patients with: A history of life-threatening infusion reaction to UPLIZNA…

WARNINGS AND PRECAUTIONS Infusion Reactions: UPLIZNA can cause infusion reactions…

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

UPLIZNA (inebilizumab-cdon) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

IMPORTANT SAFETY INFORMATION

UPLIZNA is contraindicated in patients with:

  • A history of life-threatening infusion reaction to UPLIZNA
  • Active hepatitis B infection
  • Active or untreated latent tuberculosis

WARNINGS AND PRECAUTIONS

Infusion Reactions: UPLIZNA can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash, or other symptoms. Infusion reactions were most common with the first infusion but were also observed during subsequent infusions. Administer pre-medication with a corticosteroid, an antihistamine, and an anti-pyretic.

Infections: The most common infections reported by UPLIZNA-treated patients in the randomized and open-label periods included urinary tract infection (20%), nasopharyngitis (13%), upper respiratory tract infection (8%), and influenza (7%). Delay UPLIZNA administration in patients with an active infection until the infection is resolved.

Increased immunosuppressive effects are possible if combining UPLIZNA with another immunosuppressive therapy.

The risk of Hepatitis B Virus (HBV) reactivation has been observed with other B-cell-depleting antibodies. Perform HBV screening in all patients before initiation of treatment with UPLIZNA. Do not administer to patients with active hepatitis.

Although no confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) were identified in UPLIZNA clinical trials, JC virus infection resulting in PML has been observed in patients treated with other B-cell-depleting antibodies and other therapies that affect immune competence. At the first sign or symptom suggestive of PML, withhold UPLIZNA and perform an appropriate diagnostic evaluation.

Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating UPLIZNA.

Vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation, until B-cell repletion.

Reduction in Immunoglobulins: There may be a progressive and prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued UPLIZNA treatment. Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with UPLIZNA until B-cell repletion especially in patients with opportunistic or recurrent infections.

Fetal Risk: May cause fetal harm based on animal data. Advise females of reproductive potential of the potential risk to a fetus and to use an effective method of contraception during treatment and for 6 months after stopping UPLIZNA.

Adverse Reactions: The most common adverse reactions (at least 10% of patients treated with UPLIZNA and greater than placebo) were urinary tract infection and arthralgia.

Please see Full Prescribing Information for more information.

INDICATION UPLIZNA (inebilizumab-cdon) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

IMPORTANT SAFETY INFORMATION UPLIZNA is contraindicated in patients with: A history of life-threatening infusion reaction to UPLIZNA…

WARNINGS AND PRECAUTIONS Infusion Reactions: UPLIZNA can cause infusion reactions…

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

UPLIZNA (inebilizumab-cdon) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

IMPORTANT SAFETY INFORMATION

UPLIZNA is contraindicated in patients with:

  • A history of life-threatening infusion reaction to UPLIZNA
  • Active hepatitis B infection
  • Active or untreated latent tuberculosis

WARNINGS AND PRECAUTIONS

Infusion Reactions: UPLIZNA can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash, or other symptoms. Infusion reactions were most common with the first infusion but were also observed during subsequent infusions. Administer pre-medication with a corticosteroid, an antihistamine, and an anti-pyretic.

Infections: The most common infections reported by UPLIZNA-treated patients in the randomized and open-label periods included urinary tract infection (20%), nasopharyngitis (13%), upper respiratory tract infection (8%), and influenza (7%). Delay UPLIZNA administration in patients with an active infection until the infection is resolved.

Increased immunosuppressive effects are possible if combining UPLIZNA with another immunosuppressive therapy.

The risk of Hepatitis B Virus (HBV) reactivation has been observed with other B-cell-depleting antibodies. Perform HBV screening in all patients before initiation of treatment with UPLIZNA. Do not administer to patients with active hepatitis.

Although no confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) were identified in UPLIZNA clinical trials, JC virus infection resulting in PML has been observed in patients treated with other B-cell-depleting antibodies and other therapies that affect immune competence. At the first sign or symptom suggestive of PML, withhold UPLIZNA and perform an appropriate diagnostic evaluation.

Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating UPLIZNA.

Vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation, until B-cell repletion.

Reduction in Immunoglobulins: There may be a progressive and prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued UPLIZNA treatment. Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with UPLIZNA until B-cell repletion especially in patients with opportunistic or recurrent infections.

Fetal Risk: May cause fetal harm based on animal data. Advise females of reproductive potential of the potential risk to a fetus and to use an effective method of contraception during treatment and for 6 months after stopping UPLIZNA.

Adverse Reactions: The most common adverse reactions (at least 10% of patients treated with UPLIZNA and greater than placebo) were urinary tract infection and arthralgia.

Please see Full Prescribing Information for more information.

  1. UPLIZNA (inebilizumab) [prescribing information] Horizon.
  2. SOLIRIS® (eculizumab) [prescribing information]. Alexion Pharmaceuticals, Inc.
  3. ENSPRYNG® (satralizumab-mwge) [prescribing information]. Genentech, Inc.
  4. ULTOMIRIS® (ravulizumab-cwvz) [prescribing information]. Alexion Pharmaceuticals, Inc.
  5. Data on File. Amgen; October 2024.